Gallbladder neoplasm

Related records

Broader conditions (12)

• Cancer or benign tumor
• Digestive system disorder
• Digestive system neoplasm
• Disease
• Disease by body system or component
• Disease by etiologic mechanism
• Gallbladder disorder
• Hepatobiliary disorder
• Hepatobiliary neoplasm
• Human disease
• Neoplasm
• Neoplastic disease or syndrome

Narrower conditions (27)

• Benign neoplasm of gallbladder
• Gall bladder carcinoma in situ
• Gallbladder adenocarcinoma
• Gallbladder adenoma
• Gallbladder adenosquamous carcinoma
• Gallbladder angiosarcoma
• Gallbladder biliary intraepithelial neoplasia
• Gallbladder cancer
• Gallbladder carcinoma
• Gallbladder leiomyoma
• Gallbladder leiomyosarcoma
• Gallbladder lipoma
• Gallbladder lymphoma
• Gallbladder melanoma
• Gallbladder mucinous adenocarcinoma
• Gallbladder neuroendocrine neoplasm
• Gallbladder neuroendocrine tumor, grade 1/2
• Gallbladder papillary neoplasm
• Gallbladder papillary neoplasm with an associated invasive carcinoma
• Gallbladder pleomorphic giant cell adenocarcinoma

Trials (293)

• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
• A Case Series on Incidentally Detected Gallbladder Malignancy
• A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening
• A Dual Channel Supraglottic Airway Device (LMA Gastro) for Oxygenation in Patients Undergoing ERCP
• A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers
• A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
• A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
• A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
• A Prospective Study of UCAD for Diagnosing Benign or Malignant Biliary Obstruction and Follow-up
• A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
• A Randomized, Open, Prospective Clinical Research of Fluorouracil Implant to Improve Surgical Gallbladder Cancer and Bile Duct Cancer
• A Study for Efficacy of Side-by-side Compared to Stent-in-stent Technique in the Endoscopic Management of Malignant Hilar Biliary Obstruction
• A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
• A Study of Circulating Exosome Proteomics In Gallbladder Carcinoma Patients
• A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer
• A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
• A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer
• A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
• A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
• A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts

Drugs in development (13)

• Capecitabine Phase 3
• Cisplatin Phase 3
• Copanlisib Phase 2
• Durvalumab Phase 2
• Gemcitabine Phase 3
• Gemcitabine hydrochloride Phase 3
• MK-2206 Phase 2
• Octanoic acid Phase 1
• Oxaliplatin Phase 3
• Paclitaxel Phase 2
• Porfimer sodium Phase 3
• Selumetinib Phase 2
• Somatostatin Phase 3